New issues in systemic therapy for ovarian cancer.


Most patients with ovarian cancer require systemic therapy upfront and again on recurrence. Treatment advances over the past decade have been few, but bevacizumab prolongs disease remission, if not survival. Other targeted agents have not been effective, but emerging data for experimental agents suggest this outlook may change. In her presentation at the NCCN 18th Annual Conference, Dr. Deborah K. Armstrong reviewed findings supporting intraperitoneal chemotherapy, the use of bevacizumab, the use of neoadjuvant chemotherapy, and the potential of poly (ADP-ribose) polymerase (PARP) inhibitors and other newer agents.


Citations per Year

703 Citations

Semantic Scholar estimates that this publication has 703 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Armstrong2013NewII, title={New issues in systemic therapy for ovarian cancer.}, author={Deborah Armstrong}, journal={Journal of the National Comprehensive Cancer Network : JNCCN}, year={2013}, volume={11 5 Suppl}, pages={690-3} }